Delivery Order SPE2DR25D9832-SPE2DR26FGJS4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,496.65 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Beyfortus 50 mg/0.5 mL syringes. The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, operates under a firm fixed-price structure with no set-aside designation, allowing DMS Pharmaceutical Group to compete directly against all...
- The Defense Logistics Agency awarded a delivery order valued at $36,141.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Beyfortus 100 mg/ml syringes. This firm fixed-price delivery order, issued without set-aside designation, was awarded on October 31, 2025, with an ultimate completion date of November 3, 2025. The award represents a continuation of DMS Pharmaceutical Group's substantial...
- The Defense Logistics Agency awarded a $3,559.66 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Beyfortus 50 mg/0.5 ml syringes. The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $9,053.85 order is for BEYFORTUS 100 MG/ML SYRINGEML and is part of a larger, single-award indefinite delivery contract valued up to $4,999,999 through 2025. The contract enables DLA to issue delivery orders for a broad range of pharmaceutical items to fulfill the recurring medical supply needs of military...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $15,032.56 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract covers the procurement of BEYFORTUS 100 MG/ML SYRINGEML, with a completion date of September 30, 2024. This delivery order contract is part of a larger indefinite delivery contract (IDC) under the SPE2DB program, valued at up to $499,999,999, which allows...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,834.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Beyfortus 100 mg/mL syringes. The award was issued on October 20, 2025, with an ultimate completion date of October 21, 2025, with no set-aside designation applied. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, is serving...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $5,503.02 to DMS Pharmaceutical Group Inc. for Beyfortus 100 mg/ml syringes on October 27, 2025, with completion expected by October 28, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $18,107.70 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, which runs through February 2, 2024, is for the supply of the pharmaceutical product BEYFORTUS 100 MG/ML SYRINGEML. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, holding a significant indefinite delivery contract (IDC) with the DLA under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,546.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of SYFOVRE 15 mg/0.1 mL vials. The award, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $11,829.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on October 27, 2025, with an ultimate completion date of October 28, 2025, represents a single award with no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group...
- SPE2DR25D9832Indefinite Delivery Contract
- SPE2DR25D9832-SPE2DR26FGJS4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,378.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of BEYFORTUS 50 mg/0.5 mL syringes. This firm fixed-price delivery order, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was executed without subcontractor involvement, with DMS Pharmaceutical Group serving as the sole prime contractor. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition vehicle established to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide. The underlying PPV-G GEN V program, valued at $30.3 billion, positions DMS Pharmaceutical Group as a critical regional prime vendor contractor supporting the recurring pharmaceutical and medical consumable requirements of the global military medical system. The company's established performance across diverse product categories, including specialty biologics, vaccines, oncology treatments, and emergency medications, demonstrates its capability to fulfill the specialized pharmaceutical needs of federal military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 11/14/25 |